NEW YORK, May 29, 2026
Actinium Pharmaceuticals, Inc. has announced the receipt of two patent allowances from the Canadian Intellectual Property Office (CIPO) covering its flagship Actimab-A and Iomab-ACT programs, further strengthening the company’s growing intellectual property portfolio in targeted radiotherapies and cell therapy conditioning technologies. The newly allowed patents expand protection for Actinium’s innovative approaches in acute myeloid leukemia (AML) treatment and gene-edited cell-based therapies, reinforcing the company’s leadership position in the rapidly evolving radiopharmaceutical sector. With approximately 250 issued and pending patents and patent applications worldwide, the latest allowances represent another important milestone as Actinium continues advancing next-generation cancer therapies designed to improve efficacy while reducing toxicity compared with conventional treatment approaches.
Patent Protection Expanded for Actimab-A in Acute Myeloid Leukemia
One of the newly allowed Canadian patents covers the use of Actimab-A in combination with the CLAG-M chemotherapy regimen for the treatment of acute myeloid leukemia (AML). Actimab-A is among Actinium’s most advanced clinical-stage radiotherapeutic candidates and is being developed as a potential backbone therapy for multiple hematologic malignancies. The allowance further expands intellectual property protection for a treatment approach that has already demonstrated promising clinical activity in relapsed and refractory AML patients.
The Canadian patent complements previously granted protection in Japan and builds upon ongoing patent filings in the United States and Europe. Once issued, the patent is expected to provide exclusivity through January 2039, supporting long-term development and commercialization opportunities. AML remains one of the most aggressive blood cancers worldwide, and innovative targeted radiotherapies capable of improving survival outcomes continue to represent a major area of clinical need. The expanded patent coverage strengthens Actinium’s strategic position as it advances Actimab-A toward future late-stage clinical development and potential regulatory pathways.
Iomab-ACT Strengthens Next-Generation Cell Therapy Conditioning Platform
Advertisement
The second patent allowance focuses on Iomab-ACT, Actinium’s novel CD45-targeted conditioning platform designed to prepare patients for gene-edited and adoptive cell therapies. Traditional conditioning regimens often rely on intensive chemotherapy or radiation that can result in significant toxicity. Iomab-ACT is being developed as a targeted conditioning approach intended to selectively prepare the immune system while minimizing damage to healthy tissues.
The newly allowed patent expands protection for methods utilizing anti-CD45 targeted conditioning in conjunction with gene-edited cell therapies and extends exclusivity through October 2038. The allowance builds on a previously issued U.S. patent and supports additional applications currently under review in Europe, China, and other global markets. As cell and gene therapies continue transforming the treatment landscape for cancer and genetic diseases, innovative conditioning technologies are increasingly recognized as critical components of successful therapeutic delivery. The strengthening of the Iomab-ACT intellectual property estate positions Actinium to capitalize on growing demand for safer and more effective cell therapy preparation strategies.
Expanding Leadership in Targeted Radiopharmaceutical Innovation
The latest patent milestones underscore Actinium’s broader strategy of developing a diversified pipeline of targeted radiotherapies and conditioning agents across both hematologic malignancies and solid tumors. Beyond Actimab-A and Iomab-ACT, the company continues advancing multiple oncology programs, including ATNM-400, a novel radiotherapeutic candidate with potential applications across prostate, lung, and breast cancers. The company also maintains ongoing collaborations with leading research institutions, including the National Cancer Institute (NCI), to accelerate development of innovative radiopharmaceutical approaches.
The global radiopharmaceutical market continues to attract significant industry investment due to the ability of targeted radiation therapies to precisely deliver cancer-killing payloads while reducing exposure to healthy tissues. Actinium’s expanding patent portfolio provides important protection for its scientific innovations and supports long-term commercialization opportunities. With patent protection now extending across key international markets and additional applications pending worldwide, the company is well positioned to continue advancing its next generation of precision oncology therapies aimed at transforming outcomes for patients with difficult-to-treat cancers.
Source: Actinium Pharmaceuticals press release
